Gray Stuart R, Baker Graham, Wright Annemarie, Fitzsimons Claire F, Mutrie Nanette, Nimmo Myra A
School of Sport and Exercise Sciences, Loughborough University, Leicestershire, UK.
Prev Med. 2009 Jan;48(1):39-44. doi: 10.1016/j.ypmed.2008.10.013. Epub 2008 Oct 29.
The purpose of the present study was to determine whether a community-based walking intervention, using pedometers, is effective in reducing systemic inflammatory markers.
Participants (age=49(8.9)) were recruited in Glasgow, United Kingdom, from August to December 2006 and were randomly assigned to a control (n=24; 6 males, no change in walking) and intervention group (n=24; 5 males gradually increasing walking by 3000 steps/day on 5 days of the week). Blood samples were collected at baseline, and after 12 weeks, and analysed for glucose, insulin, high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), tumour necrosis factor-alpha (TNF-alpha) and soluble TNF receptors I and II (sTNFR1 and sTNFRII).
In the control group baseline step counts were 6356 (2953) steps/day and did not change (P>0.05) after 12 weeks, 6709 (2918) steps/day. The intervention group increased (P<0.001) step count from 6682 (3761) steps/day at baseline to 10182 (4081) steps/day at 12 weeks. Over the 12 week period there was no change in any other variables measured, in either control or intervention group.
We conclude that the current community-based intervention did not affect systemic markers of inflammation or insulin sensitivity.
本研究旨在确定基于社区的计步器步行干预措施是否能有效降低全身炎症标志物水平。
2006年8月至12月在英国格拉斯哥招募参与者（年龄=49（8.9）岁），并将其随机分为对照组（n=24；6名男性，步行量无变化）和干预组（n=24；5名男性，每周5天逐渐增加至每天多走3000步）。在基线时以及12周后采集血样，分析血糖、胰岛素、高敏C反应蛋白（hsCRP）、白细胞介素-6（IL-6）、可溶性IL-6受体（sIL-6R）、肿瘤坏死因子-α（TNF-α）以及可溶性TNF受体I和II（sTNFR1和sTNFRII）。
对照组基线步数为每天6356（2953）步，12周后无变化（P>0.05），为每天6709（2918）步。干预组步数从基线时的每天6682（3761）步增加到12周时的每天10182（4081）步（P<0.001）。在12周期间，对照组和干预组所测量的任何其他变量均无变化。
我们得出结论，当前基于社区的干预措施并未影响炎症的全身标志物或胰岛素敏感性。
